63 results
424B3
PRFX
PainReform Ltd
19 Jan 24
Prospectus supplement
4:30pm
and future product candidates;
the impact of the COVID-19 pandemic and other pandemics on our operations;
our limited experience managing clinical
F-3
PRFX
PainReform Ltd
12 Jan 24
Shelf registration (foreign)
4:15pm
product candidates;
the impact of the COVID-19 pandemic and other pandemics on our operations;
our limited experience managing clinical trials;
our
6-K
EX-99.3
PRFX
PainReform Ltd
15 Nov 23
Condensed Financial Statements
4:09pm
and other research regarding PRF-110 and future product candidates; the impact of the COVID-19 pandemic on our operations; our limited experience
6-K
EX-99.2
PRFX
PainReform Ltd
15 Nov 23
Condensed Financial Statements
4:09pm
shareholders’ equity requirements under the Nasdaq rules; and
the impact of the COVID-19 pandemic, the Russian invasion of Ukraine and war between Israel
6-K
EX-99.1
PRFX
PainReform Ltd
11 Sep 23
Trial completion and results expected in mid-2024
8:41am
candidates; the impact of the COVID-19 pandemic on our operations; our limited experience managing clinical trials; our ability to retain key personnel
424B3
cl81w
5 Sep 23
Prospectus supplement
4:16pm
F-1
9p56y6j0m8 vtxy
25 Aug 23
Registration statement (foreign)
4:15pm
6-K
EX-99.2
idqol
10 Aug 23
Current report (foreign)
4:18pm
6-K
EX-99.3
79pay
10 Aug 23
Current report (foreign)
4:18pm
6-K
EX-99.1
z3g8qmlzgz2b3ed
19 Jul 23
Current report (foreign)
9:08am
424B5
tr0o5efz5
18 Jul 23
Prospectus supplement for primary offering
11:59am
6-K
EX-99.1
29antp
14 Jul 23
PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct
3:45pm
424B5
qpinuha4qi7crh
14 Jul 23
Prospectus supplement for primary offering
12:26pm
6-K
EX-99.1
w49srif70bd8z 0y2
12 Jul 23
PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement
9:23am
6-K
EX-99.1
22yv4d5 he
7 Jun 23
PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of
4:33pm
6-K
EX-99.1
ywguj7p1ku6kls6rs qt
18 May 23
PainReform Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3
9:10am
6-K
EX-99.3
9oyen7f t6indn7an
15 May 23
Condensed Financial Statements
4:51pm
6-K
EX-99.1
0y709aku0q9
1 May 23
PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery
8:41am
6-K
EX-99.1
72vmjiye 32
25 Nov 22
Annual General Meeting of Shareholders to Be
4:30pm
6-K
EX-99.1
evoef
15 Nov 22
PainReform Provides Business Update for the Third Quarter of 2022
8:47am